Weight Loss Clinical Trial
Official title:
Intermittent Fasting as a Means to Lose Fluid Overload and Weight in Complicated Obesity: a Pilot Feasibility Study
To examine the feasibility of intermittent fasting (36h, twice a week, unlimited salt and calorie-free fluid consumption), over three months, on body weight and composition in complicated obesity in whom age and medical complexity exclude the possibility of bariatric surgery.
Rationale:
Complicated obesity: In weight loss-targeted treatment of obesity, current therapeutic
choices include lifestyle modification, drug therapy, and bariatric surgery. For
uncomplicated obesity, all the above comprise legitimate means. Attempted weight loss is
traditionally initiated by targeting lifestyle, but unfortunately, the long term effect of
this approach is limited as regards success rate, the extent of the achieved weight loss and
the ability to sustain the achieved weight loss. The use of drugs is mostly reserved for
cases where a limited weight loss of 5-10% is considered satisfactory. The safety of
drug-assisted weight loss in older obese subjects with co-morbidities such as fluid
retention, nephropathy, and heart failure remains insufficiently studied. Even for older
subjects without such dominant conditions, data is scarce. For example, two trials (using
phentermine/topiramate and liraglutide) have documented efficacy analyses between older
adults and their younger, but enrolled only 7% (n= 5254) and 6.9% (n= 5232) older adults,
respectively, among their study subjects. It is now well established that in non-elderly
subjects, bariatric surgery is followed by substantial weight loss and leads to the cure of
obesity and at least to a temporary amelioration/delay/cure of its sequels, including
diabetes and hypertension.
However, weight loss is often most critically needed in subjects with complicated obesity, in
whom an overall poor health state precludes bariatric surgery altogether. Individuals with
long-standing obesity complicated by previous cardiovascular events, diabetes, renal
impairment, fluid retention due to renal disease, the use of vasodilator drugs needed to
control hypertension (alpha-blockers, calcium channel blocker), left ventricular diastolic
dysfunction, respiratory dysfunction including obstructive sleep apnea, pulmonary
hypertension, and restrictive lung disease. Such patients are generally too sick to be
considered for bariatric surgery. In such patients concomitant weight loss from two body
compartments could be extremely beneficial: reduction in fat mass and, often more critical in
immediate terms, rapid loss of excess body fluids. In obesity complicated by clinically
significant fluid retention, most of the excessive fluid volume is extra-vascular, residing
in the extracellular tissue compartment, with only a small, though critical excess, occupying
the intracellular compartment. Diuretics are the key tool to reduce volume overload, but they
acutely lower the volume of the intravascular fluid compartment, which leads to impairment in
renal, myocardial and general tissue arterial perfusion, thus often exacerbating renal
failure and overall tissue hypoperfusion, including cerebral, myocardial and hepatic blood
supply.
Most older and significantly obese subjects have had sustained obesity for several decades,
which has allowed the cumulative evolution of at least some additional comorbidities such as
the metabolic syndrome, diabetes, hyperlipidemia coronary heart disease, carotid artery
stenosis and/or uncontrolled hypertension, congestive heart failure and renal disease.
Paradoxically, then, those older subjects with a complex disease profile, who obviously
comprise poor candidates for bariatric surgery, are also the group with the greatest
immediate need to lose weight. It is therefore noteworthy that in Israel, individuals over
the age of 65 cannot undergo bariatric surgery on the basis of obesity per se, unless
approved by a special committee. Although European guidelines for the treatment of obesity in
the elderly have concluded that the elderly should not be denied bariatric surgery solely on
age grounds, long-term evidence in support of this statement is lacking such that both
patients and physicians often consider bariatric surgery at this stage as too risky. Thus,
current standard medical practice has little to offer to the complicated older obese patient
who, on one hand is burdened with incapacitating obesity and its complications, and, on the
other hand, is beyond the reach of the only tool to permanently alleviate obesity, i.e.,
bariatric surgery.
Intermittent and or short term fasting in humans: There is truly a lack of solid work on the
safety and efficacy of fasting as a tool to lose weight in humans. The largest medical
database on fasting has been collected on subjects practicing religious fast, such as the
Ramadan. However, these forms of fasting are almost uniformly compensated for by excessive
feeding either in the beginning or the end of the fast, or both. Insights on the effects of
true fasting, longer than 24h, under medical supervision in humans is hard to find in
published reports. In one study where caloric restriction for most of the week was combined
with one day/week of nearly complete fasting (125Kcal), the intervention was deemed effective
and unassociated with untoward effects in 54 obese women over a period of 24 weeks. A recent
review included 16 studies of intermittent fasting in humans, of which 11 were carried out in
overweight or obese subjects. Duration of the trials varied from 24h to 6 months. In two
studies, fasting was daily and lasted from 11 and 16 hours within each day. There were 7
studies lasting 8-12 weeks, with alternate-day fasting, in which fasting was defined as
consuming 20-30% of the required caloric intake on the fasting day. In two studies, caloric
restriction was defined as consuming 25% less calories on the fasting day. As compared to a
variety of more standard dietary measures, intermittent fasting appears to result in some
modestly larger weight reduction. Among 16 intervention trials included in review, 11
reported statistically significant weight loss. However, in most of the reviewed intervention
trials, complete fasting was either not attempted or restricted to 16 hours only, or less.
Complete intermittent fasting (excluding water) in humans: Despite the lack of data on the
effects of complete intermittent fasting, however, a day of fasting is semi/non-intentionally
practiced in many subjects undergoing investigative diagnostic procedures such as combined
endoscopy and colonoscopy conducted in the afternoon or surgery unexpectedly postponed to the
evening hours and many other medical conditions. Unfortunately, this unwanted form of fasting
was never studied in depth. However, as early as the late 50s and early 60s of the previous
century, it was noted that 5-7 days of complete fasting was associated with diuresis,
natriuresis, and weight loss and appeared an effective mode of treatment of the failing
heart, in otherwise treatment-refractory subjects who were, at that time, already "fully
digitalized". An unexpected finding was the observation that water and salt excretion was
enhanced during fasting: one of the fasting patients with heart failure lost 7.3 kg in 5
days, and the average daily weight loss of his 10 original subjects 0.85 kg to 1.5 kg per
day, way above what might have been expected by the effect of negative caloric balance on fat
and lean tissue loss alone.
Fasting diuresis and fasting as an ancillary tool to lower fluid overload Although it is well
known that fasting in obese subjects is associated with natriuresis and development of
cumulative negative sodium balance, the mechanism of increased urinary sodium excretion
remains largely obscure. The leading hypothesis in recent decades was that reduction in
insulin ameliorated increased insulin-driven re-absorption of sodium in the kidney, but
overall, following the initial discovery of this phenomenon, it has attracted little
research. It is also well established that the obese state, even uncomplicated by renal
disease or congestive heart failure, is accompanied by a diminished ability to excrete salt.
During starvation, there appears to be an obligatory sodium loss in linkage to the
metabolically generated organic anions, which further enhances fasting related natriuresis.
Notably, unlike the action of diuretics and the tubular inhibition of sodium reabsorption,
which lowers intravascular volume, the formation of organic anions during starvation takes
place in the extravascular compartment, particularly in fat tissue, and would therefore allow
the recruitment of tissue sodium (coupled to organic anions formed during lipolysis, and
water), followed by the shift of sodium and water from the extravascular compartment to the
intravascular compartment, and only then, excretion via the kidney. The latter process,
therefore, does not lower intravascular fluid volume and should not impair renal perfusion
and function. In support of this concept is the apparent dissociation between sodium and
chloride excretion that has been reported with a relatively minimal increase in chloride
excretion during the first week of fasting when sodium excretion is rapidly increasing. In
fact, during the initial 3 days of fast in obese humans, natriuresis was proportional to
urinary 3beta hydroxybutyrate excretion while urinary ammonium had not yet increased, thus
indicating that the organic acids generated during lipolysis are the driving force in the
shift of sodium from the body, outwards through the kidneys.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Terminated |
NCT03316105 -
Effect of T6 Dermatome Electrical Stimulation on Gastroduodenal Motility in Healthy Volunteers
|
N/A | |
Completed |
NCT03700736 -
The Healthy Moms Study: Comparison of a Post-Partum Weight Loss Intervention Delivered Via Facebook or In-Person Groups
|
N/A | |
Active, not recruiting |
NCT04353726 -
Knowledge-based Dietary Weight Management.
|
N/A | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03377244 -
Healthy Body Healthy Souls in the Marshallese Population
|
N/A | |
Completed |
NCT02877004 -
LLLT for Reducing Waste Circumference and Weight
|
N/A | |
Active, not recruiting |
NCT04327141 -
Low Sugar Protein Pacing, Intermittent Fasting Diet in Men and Women
|
N/A | |
Completed |
NCT03929198 -
Translation of Pritikin Program to the Community
|
N/A | |
Recruiting |
NCT05249465 -
Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention
|
N/A | |
Recruiting |
NCT05942326 -
Sleep Goal-focused Online Access to Lifestyle Support
|
N/A | |
Completed |
NCT00535600 -
Effects of Bariatric Surgery on Insulin
|
||
Not yet recruiting |
NCT03601273 -
Bariatric Embolization Trial for the Obese Nonsurgical
|
Phase 1 | |
Active, not recruiting |
NCT04357119 -
Common Limb Length in One-anastomosis Gastric Bypass
|
N/A | |
Completed |
NCT03210207 -
Gastric Plication in Mexican Patients
|
N/A | |
Completed |
NCT03139760 -
POWERSforID: A Telehealth Weight Management System for Adults With Intellectual Disability
|
N/A | |
Completed |
NCT02945410 -
Effect of Caloric Restriction and Protein Intake on Metabolism and Anabolic Sensitivity
|
N/A | |
Completed |
NCT02948517 -
Time Restricted Feeding for Weight Loss and Cardio-protection
|
N/A | |
Recruiting |
NCT02559479 -
A Study to Assess the Effect of a Normal vs. High Protein Diets in Carbohydrates Metabolism in Obese Subjects With Diabetes or Prediabetes
|
N/A |